Today: 21 May 2026
Berkshire Hathaway stock price dips into the weekend: BRK.B closes lower as Fed week and Kraft Heinz filing loom
24 January 2026
2 mins read

Berkshire Hathaway stock price dips into the weekend: BRK.B closes lower as Fed week and Kraft Heinz filing loom

New York, Jan 24, 2026, 05:43 EST — Market closed.

  • Berkshire Hathaway’s Class B shares dropped 1.1% on Friday, with Class A shares also edging lower.
  • With the Fed decision looming and a packed week of megacap earnings ahead, investors brace for moves that could shift the major indexes.
  • A Kraft Heinz filing registered Berkshire’s shares for potential resale but didn’t indicate any planned transaction.

Berkshire Hathaway Inc.’s Class B shares slipped 1.1% Friday, finishing at $478.97. The stock ended the week weaker ahead of the U.S. market’s weekend closure. Meanwhile, Berkshire’s Class A shares dropped 1.0% to $720,932.18.

The timing is crucial. Next week features a Federal Reserve policy decision alongside a packed schedule of quarterly earnings from major tech giants — both key drivers for risk appetite and overall equity flows. “It’s been a little bit of a short but steep roller-coaster ride,” said Yung-Yu Ma, chief investment strategist at PNC Financial Services Group. Reuters

Berkshire investors now have a new signal to consider. A Kraft Heinz Company filing from Jan. 20 revealed the food giant submitted a prospectus supplement registering the possible resale of up to 325,442,152 shares by Berkshire Hathaway. The filing makes clear this “is not itself a sale” and doesn’t guarantee Berkshire will unload any shares. Kraft Heinz also noted it would get no proceeds from a sale and confirmed no new securities would be issued.

Berkshire Hathaway’s shares dipped as Wall Street closed out a choppy week with the Dow off 0.58% on Friday. The S&P 500 held steady, while the Nasdaq managed a 0.28% gain. Intel took a hit after lowering its outlook, drawing attention ahead of a heavy slate of megacap earnings next week. “We’re feeling pretty good, but mindful we might have some significant twists and turns,” said Jason Blackwell, chief investment strategist at Focus Partners Wealth. Reuters

Berkshire’s Class B shares saw heavy action Friday, with roughly 5.4 million changing hands—well above the 50-day average of about 4.8 million, according to MarketWatch. The stock still lingers around 11.6% below its 52-week peak of $542.26 but has gained roughly 3.7% so far this year.

Kraft Heinz shares closed Friday up 2.0%, reaching $23.20. At that price, Berkshire’s registered stake would be worth about $7.6 billion if liquidated.

Rate expectations are creating another headwind. Berkshire’s insurance units produce huge pools of investable cash, and moves in short-term rates directly impact returns on these cash-like assets. At the same time, rising yields tend to put pressure on stock valuations across the board.

The downside risk is clear if inflation remains stubborn and trade-related costs climb. A Reuters report on Friday referenced a survey where companies flagged import tariffs as a key driver of higher prices. Chris Williamson from S&P Global noted that “increased costs, widely blamed on tariffs,” are once again a major factor behind rising prices. If inflation pressures stick around, interest rates could stay elevated for longer, forcing a market repricing that would hit equities, including Berkshire. Reuters

As U.S. markets reopen Monday, all eyes will be on whether Berkshire can regain its footing after Friday’s dip and if Kraft Heinz’s prospectus filing leads to any concrete moves. Berkshire’s next key date is its annual shareholder meeting in Omaha on May 2, per the company.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Fortinet stock jumps on TD Cowen upgrade — what FTNT investors watch before earnings
Previous Story

Fortinet stock jumps on TD Cowen upgrade — what FTNT investors watch before earnings

Disney stock slips into weekend as board flags CEO pick “early 2026” and earnings loom
Next Story

Disney stock slips into weekend as board flags CEO pick “early 2026” and earnings loom

Go toTop